Outcome after initial cladribine for HCL (response rates, progression-free, and overall survival)
| Response comparisons . | VH4-34+ . | VH4-34− . | P . | HCLv . | HCL . | P . |
|---|---|---|---|---|---|---|
| Complete remission rate (%) | 0/13 (0) | 14/48 (29) | .03 | 1/15 (7) | 13/46 (28) | .15 |
| Complete/hematologic remission rate (%) | 2/13 (15) | 30/48 (63) | .004 | 3/15 (20) | 29/46 (63) | .006 |
| Major response rate (%) | 2/13 (15) | 40/48 (83) | .00001 | 4/15 (27) | 38/46 (83) | .0001 |
| Median progression-free survival, mo (n) | 5.1 (13) | 22.8 (48) | .007 | 5.1 (15) | 23.1 (46) | .02 |
| Median overall survival, y (n) | 8.63 (14) | 26.22 (68) | < .0001 | >8.79 (20) | 26.22 (62) | .02 |
| Major response rate for classic HCL only (%) | 2/6 (33) | 36/40 (90) | .006 | |||
| Major response rate for those VH4-34− only (%) | 4/8 (50) | 36/40 (90) | .02 | |||
| Median overall survival, y, classic HCL only (n) | 4.70 (6) | 26.64 (56) | < .0001 | |||
| Median overall survival, y, VH4-34− only (n) | >4.74 (12) | 26.64 (56) | .22 | |||
| Median age at diagnosis, age > 50 y (n) | 55.75 (12) | 57.00 (24) | .31 | 60.8 (13) | 56.70 (23) | .1 |
| Median overall survival, age > 50 y (n) | 8.63 (12) | 21.05 (24) | .0001 | 8.79 (13) | 16.53 (23) | .11 |
| Median overall survival, age > 50 y, classic HCL only | 4.70 (5) | 17.33 (18) | < .0001 | |||
| Median overall survival, age > 50 y, VH4-34− only | 21.05 (6) | 17.33 (18) | .23 |
| Response comparisons . | VH4-34+ . | VH4-34− . | P . | HCLv . | HCL . | P . |
|---|---|---|---|---|---|---|
| Complete remission rate (%) | 0/13 (0) | 14/48 (29) | .03 | 1/15 (7) | 13/46 (28) | .15 |
| Complete/hematologic remission rate (%) | 2/13 (15) | 30/48 (63) | .004 | 3/15 (20) | 29/46 (63) | .006 |
| Major response rate (%) | 2/13 (15) | 40/48 (83) | .00001 | 4/15 (27) | 38/46 (83) | .0001 |
| Median progression-free survival, mo (n) | 5.1 (13) | 22.8 (48) | .007 | 5.1 (15) | 23.1 (46) | .02 |
| Median overall survival, y (n) | 8.63 (14) | 26.22 (68) | < .0001 | >8.79 (20) | 26.22 (62) | .02 |
| Major response rate for classic HCL only (%) | 2/6 (33) | 36/40 (90) | .006 | |||
| Major response rate for those VH4-34− only (%) | 4/8 (50) | 36/40 (90) | .02 | |||
| Median overall survival, y, classic HCL only (n) | 4.70 (6) | 26.64 (56) | < .0001 | |||
| Median overall survival, y, VH4-34− only (n) | >4.74 (12) | 26.64 (56) | .22 | |||
| Median age at diagnosis, age > 50 y (n) | 55.75 (12) | 57.00 (24) | .31 | 60.8 (13) | 56.70 (23) | .1 |
| Median overall survival, age > 50 y (n) | 8.63 (12) | 21.05 (24) | .0001 | 8.79 (13) | 16.53 (23) | .11 |
| Median overall survival, age > 50 y, classic HCL only | 4.70 (5) | 17.33 (18) | < .0001 | |||
| Median overall survival, age > 50 y, VH4-34− only | 21.05 (6) | 17.33 (18) | .23 |
HCL indicates classic hairy cell leukemia; and HCLv, variant HCL.